					· · · · · · · · · · · · · · · · · · ·			SHEET	<u> 1 OF 1</u>		
INFO	CIT	'ΑΤ	ON DISCLOS ION IN AN	SURE	ATTÝ. DOCKET NO. 064162-0032	1	erial no. 0/509,513				
DEC 2 8 2006 APPLICATION					APPLICANT Gerald Wayne BOTH, et al.						
AT COMMENT		(PT	O-1449)		FILING DATE October 24, 20	1			1633		
- Alasa			U	.S. PATEN	T DOCUMENTS						
EXAMINER'S INITIALS	CITE NO.	Nur	Document Number mber-Kind Code2 (4 known)	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Ш									
· · · · · · · · · · · · · · · · · · ·	0.3	H	·····								
			;								
	<u> </u>	US	·								
·	<u> </u>	US									
<u>-</u>	 	US									
		US	4				<u> </u>				
	·, i			FOREIGN PA	ATENT DOCUMENTS						
INTERIOR I			Publication Date MM-DD-YYYY		Where	s, Columns, Lines Translation There Relevant igures Appear Yes No					
	ļ	 				<u> </u>					
	 	 				 					
		 				 					
. 1											
	·										
EVALUE DIO	·	T 11			hor, Title, Date, Pertinent Pages, I	•		 			
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.									
/RMK/		VOEKS, D. ET AL, "Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside prosphorylase and fludarabine in mouse medels" Gene Therapy, 9(12), 769-768-GODEN: GETHEC; ISSN; 0969-7128, 2002, XP002399217									
/RMK/	t,		LOCKETT, LINDA J. ET AL: "Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors" CLINICAL CANCER RESEARCH, 3(11), 2075-2080 CODEN: CCREF4; ISSN: 1078-0432, 1997, XP002399218								
/RMK/		FELGNER J H ET AL: "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 28 Jan 1994, vol. 269, no. 4, pages 2550-2581, XP002399219									
/RMK/		MINCHEFF M ET AL: "Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial" EUROPEAN UROLOGY, S. KARGER AG., BASEL, CH, vol. 38, no. 2, August 2000, pages 208-217, XP002957430									
	/Robert		aminer y/ (08/29/2007)	-	:	DATE CONSIDERED 08/29/2007					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

DT04 Rec'd PCT/PTO 2 8 SEP 2004

SHEET 1 OF 1

INFC	CIT	ATI	N DISCLO ON IN AN CATION	SURE	ATTY. DOCKET NO. 64162-032	SERIAL NO. Not yet assigned 10/509513				
: :			: 1	·	APPLICANT Gerald W. BOTH, et al.					
	h	(PTC)-1449)			September 28, 2004 Not yet assigned 1632			.1632	
1.1.				U.S. PATE	NT DOCUMENTS				:	
EXAMINER'S INITIALS	CITE NO.	1	cument Number er-Kind Code2 (7 known)	Publication Dat MM-DD-YYYY					es or Relevant	
/RMK/		US	5,906,922	05/25/1999	Whittaker et a	ıl.				
/RMK/	1. 1	us: '	5,854,224	12/29/1998	Lockett et al					
ļ		US		ļ						
		US		ļ						
	-	US	i	<u> </u>	· · · · · · · · · · · · · · · · · · ·		 			
		US	· · · · · · · · · · · · · · · · · · ·	 						
		us					-			
,	ļ	us					 			
7.		us		:						
	;	us	: •							
		US		<u> </u>	· · · · · · · · · · · · · · · · · · ·					
		US							- 1	
		บร								
	1 1				ATENT DOCUMENTS	-9				
EXAMINER'S INITIALS	CITE NO.	Country	n Patent Document Codes-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Trans Where Relevant Figures Appear		anslation		
1.1		ļ,						Yes	No	
MK			NU-A-27888/00 O # WO 00/52158)	09/21/2000 ;	COMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION			***		
	ļ	 		ļ						
	ļ	1		 	 					
	-		· · · · · · · · · · · · · · · · · · ·		+				- :	
		<u> </u>	OTHER A	RT (Including Auth	nor, Title, Date, Pertinent Pages, E	tc.)				
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
/RMK/		VC			state cancer delivered by ovine a rabine in mouse models." Gene					
7RMK/	,		LU, Yi, "Viral Based (Sene Therapy for	Prostate Cancer." Current Gen	e Therapy, Volu	me 1, pp	183-200		
/RMK/		SECRIST, K., et al. " Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with E. Coll Purine Nucleoside Phosphorylase." Nucleosides and Nucleotides, 18/4-5, pp. 745-757								
/RMK/		ANDERSON , Leonard, M., et al. " Breast cancer-specific expression of the Candida albicans cystosine deaminase gene using a transcriptional targeting approach." Cancer Gene Therapy, 7/6, pp.845-852								
/R	obert K	exam (elly/ ((INER 08/29/2007)		08/29	DATE CONSIDERED 08/29/2007				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.